Covid or not, venture financing breaks records
Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.
Third-quarter events to watch for large drug makers
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
Akero’s success gives a new Nash mechanism hope
Before Covid-19 came along investors were looking to several Nash catalysts in 2020, and yesterday Akero delivered on one of these.
Astra and Daiichi lay out their plan for a better Herceptin
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
